William A. Ackman’s actions in the bid for Allergan have raised questions about how well the insider-trading rules have protected investors, Peter J. Henning writes in White Collar Watch.
via NYT > Business Day http://ift.tt/1nWz1zZ
via WordPress http://ift.tt/1h7oTzX
via All Business Is Good Business http://ift.tt/1nWGrU3
via May 21st 2011 wrong http://ift.tt/1ixEey9
No comments:
Post a Comment